[{"id":"171fd9a4-54b8-4201-b9ff-abcc3c8df63a","acronym":"NIPU","url":"https://clinicaltrials.gov/study/NCT04300244","created_at":"2024-02-29T19:31:36.820Z","updated_at":"2025-02-25T14:29:07.915Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma","source_id_and_acronym":"NCT04300244 - NIPU","lead_sponsor":"Åslaug Helland","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Leukine (sargramostim) • UV1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 05/04/2020","start_date":" 05/04/2020","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 03/15/2027","study_completion_date":" 03/15/2027","last_update_posted":"2024-02-29"},{"id":"65549955-d067-4c21-bc42-ff091226f6d2","acronym":"UV1-103","url":"https://clinicaltrials.gov/study/NCT03538314","created_at":"2021-01-18T17:26:03.967Z","updated_at":"2024-07-02T16:36:00.254Z","phase":"Phase 1","brief_title":"UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT03538314 - UV1-103","lead_sponsor":"Ultimovacs ASA","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • UV1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2022-11-17"},{"id":"4823acf0-a35f-46e1-8e02-1a70ad0be285","acronym":"FOCUS","url":"https://clinicaltrials.gov/study/NCT05075122","created_at":"2021-10-12T14:53:00.645Z","updated_at":"2024-07-02T16:36:15.736Z","phase":"Phase 2","brief_title":"Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab","source_id_and_acronym":"NCT05075122 - FOCUS","lead_sponsor":"Martin-Luther-Universität Halle-Wittenberg","biomarkers":" PD-L1 • IFNG","pipe":"","alterations":" ","tags":["PD-L1 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Leukine (sargramostim) • UV1"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-03-09"}]